What the board approved
At its 31 July 2026 meeting, the board of Bajaj Finserv took three actions. It approved the unaudited standalone and consolidated results for the quarter ended 30 June 2026, carried with limited-review reports bearing unmodified (unqualified) opinions. It approved the issue of equity shares of Re.1 face value to the Bajaj Finserv ESOP Trust at applicable grant prices. And — the step beyond the routine — it granted approval to pursue a re-insurance business through a subsidiary yet to be incorporated, a move the filing states is subject to the approval of IRDAI and other authorities.
The quarter, in brief
On a consolidated basis, the group reported year-on-year growth in total income and profit after tax versus Q1 FY26, per the company's press release. Profit attributable to owners rose more modestly than headline PAT, reflecting the group's holding structure across listed and unlisted subsidiaries. The company noted that Ind AS treatment of the insurance subsidiaries' equity portfolios — part held at fair value through profit and loss — can cause temporary mark-to-market volatility in reported results.
Among the operating businesses, the filing described Bajaj Finance's consolidated profit growing 28% and its mortgage arm BHFL 23%; Bajaj General's gross written premium up 11%; and Bajaj Life's net value of new business up 87%. Bajaj General's profit after tax was lower year-on-year, which the release attributed largely to lower profit on sale of investments.
The re-insurance decision in context
The re-insurance approval is a directional step, not a completed transaction. The filing discloses only the board's in-principle go-ahead to incorporate a subsidiary for the business; it names no capital commitment, timeline or partner, and makes the step conditional on regulatory clearance. For a group already spanning life, general and health insurance through majority-held subsidiaries, this would extend its footprint into risk-carrying for other insurers, if and when approvals are secured.